- Apr 2, 2009
- 5,171
- 13,288
- 67
The FDA has fined Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc. more than $1.6 billion for marketing a "misbranded" drug
FDA: Janssen Pharmaceuticals, Inc. to plead guilty and pay over $1.6 billion to resolve allegations of misbranding and filing false claims for its schizophrenia drug Risperdal
If the FDA imposes the deeming and other regs on e-cigs, >99% of e-cig products now on market will likely be labelled as "misbranded" tobacco products, with manufacturers facing somewhat similar prosecutorial actions by FDA and Justice Dept as J&J just received.
Please note that any tobacco product (including any e-cig product, if the deeming reg is imposed) FDA doesn't officially approve (by approving a Substantially Equivalent or New tobacco Product application) will be considered "misbranded" by the Tobacco Control Act, and FDA will issue a cease and desist letter to the manufacturer/importer.
FDA: Janssen Pharmaceuticals, Inc. to plead guilty and pay over $1.6 billion to resolve allegations of misbranding and filing false claims for its schizophrenia drug Risperdal
If the FDA imposes the deeming and other regs on e-cigs, >99% of e-cig products now on market will likely be labelled as "misbranded" tobacco products, with manufacturers facing somewhat similar prosecutorial actions by FDA and Justice Dept as J&J just received.
Please note that any tobacco product (including any e-cig product, if the deeming reg is imposed) FDA doesn't officially approve (by approving a Substantially Equivalent or New tobacco Product application) will be considered "misbranded" by the Tobacco Control Act, and FDA will issue a cease and desist letter to the manufacturer/importer.
Last edited: